Fulcrum-Slate Merger Gives Existing Fulcrum Holders 5% Stake, Adds $245 Million Financing

Fulcrum Therapeutics and privately held Slate Medicines agreed to merge in an all-stock transaction that will leave existing Fulcrum shareholders with only 5.0% of the combined company on the current pro forma assumptions. Pre-merger Slate holders excluding the new financing investors are expected to own 55.9%, while investors providing a concurrent $245 million private placement are expected to own 39.1%.

The financing is not the purchase price for Slate. It is a separate capital raise into Slate immediately before the merger, with the newly issued Slate shares converting into Fulcrum common stock under the same exchange-ratio framework used for the combination. At the same time, Fulcrum expects to return most of its remaining net cash to its current shareholders through an estimated $270 million special dividend before the deal closes.

Fulcrum and Slate announced the transaction Monday after Fulcrum launched a review of strategic alternatives in June following the end of its lead drug program. The combined company is expected to operate under the Slate Medicines name, trade on Nasdaq under the ticker SLTE and be led by Slate Chief Executive Gregory Oakes. The companies expect the merger and financing to close in the fourth quarter of 2026, subject to shareholder, regulatory and other closing conditions.

Existing Fulcrum holders get 5% plus a cash dividend

The ownership split is driven by the valuations and financing assumptions written into the merger agreement. Fulcrum’s SEC filing says the exchange-ratio formula assumes a $31.3 million valuation for Fulcrum, subject to adjustment for its net cash at closing, and a $350 million valuation for Slate before counting proceeds from the new financing. The same formula assumes the full $245 million private placement.

On that basis, legacy Fulcrum holders are expected to own 5.0% of the fully diluted combined company. Existing Slate holders other than the financing investors are expected to own 55.9%, and the financing investors are expected to own 39.1%. The percentages exclude shares reserved for future grants under the new company’s 2026 equity incentive and employee stock purchase plans, and the final split can move if Fulcrum’s closing net cash differs from the assumptions in the merger agreement.

The $31.3 million value assigned to Fulcrum for exchange-ratio purposes is only one part of what its current shareholders are expected to receive. Fulcrum also plans to declare a cash dividend equal to the amount by which its net cash at closing exceeds $20.3 million. The companies currently estimate that distribution at about $270 million in aggregate, leaving roughly $20.3 million of Fulcrum net cash in the combined company.

That structure helps explain why the merger ownership percentages look so different from Fulcrum’s recent balance sheet. Fulcrum reported $318.8 million of cash, cash equivalents and marketable securities as of June 30, but the dividend is based on net cash at closing, not that quarter-end balance. Fulcrum has also said it expects continuing cash outflows for restructuring, facility-exit costs and professional and advisory fees as it completes its strategic review and transaction process.

The $245 million financing becomes 39.1% of the new equity

The private placement is central to the recapitalization. Slate signed the securities purchase agreement on August 16 with a group of existing Slate shareholders and new investors. The syndicate is led by Frazier Life Sciences and also includes Forbion, RA Capital Management, Deep Track Capital, Foresite Capital, OrbiMed, RTW Investments and Mingxin Capital.

Under the purchase agreement, those investors will buy approximately $245 million of Slate common stock immediately before the merger. Once the combination closes, those shares are converted into Fulcrum common stock according to the merger exchange ratio. That is why the financing group is expected to emerge with 39.1% of the fully diluted public company rather than simply becoming a cash provider sitting outside the ownership structure.

The SEC filing also makes clear that the financing is tied to the merger closing. One of the closing conditions requires an executed purchase agreement for the concurrent investment to remain in force and to provide approximately $245 million in cash proceeds to the combined company immediately before or following closing. In other words, the capital raise is not presented as an optional follow-on financing that could happen later.

Slate has also agreed to registration-rights terms for the investors. The combined company is expected to file a resale registration statement with the SEC within 30 business days after the financing closes, with effectiveness timing dependent on whether the SEC reviews the filing. Those provisions give the private-placement investors a path toward registered resale of their shares after closing, subject to the agreement and securities-law requirements.

The companies say the post-closing cash balance is expected to fund Slate’s planned operations into 2029. The stated use includes advancing SLTE-1009 through a Phase 1 healthy-volunteer study and a Phase 2 dose-ranging study in migraine patients, along with work on the broader Slate pipeline. That runway is a company forecast rather than a guaranteed funding horizon, but it shows why the financing materially changes the scale of the business that Fulcrum shareholders will own a minority interest in after closing.

Slate takes control of the public company

The governance terms reinforce the ownership math. At the effective time of the merger, Fulcrum’s board is expected to have five members, all designated by Slate. Oakes is expected to lead the combined company, and Fulcrum plans to seek shareholder approval to change its corporate name to Slate Medicines and complete a reverse stock split at a ratio to be agreed by the two companies. The combined company is expected to continue trading on Nasdaq under the new SLTE symbol.

For Fulcrum, the transaction follows a rapid change in strategy. After discontinuing development of pociredir in June, the company ceased research and development activities and cut its workforce by about 85%, from 57 full-time employees to nine. Its board began a comprehensive strategic review that included a merger, acquisition, business combination, asset sale or other transaction, with Leerink Partners advising the company.

The Slate deal therefore does more than add a new drug candidate to Fulcrum’s pipeline. Economically, it moves control of the listed company to Slate’s existing owners and the new financing group, while legacy Fulcrum shareholders receive a large cash distribution and retain a 5% fully diluted stake in the company that remains. That residual ownership gives them exposure to Slate’s future programs, but the management, board, name and overwhelming majority of the equity are expected to come from the Slate side of the transaction.

Closing still requires Fulcrum shareholder approval for the share issuance and other voting proposals, approval from the required Slate shareholders, an effective Form S-4 registration statement, expiration or termination of the applicable Hart-Scott-Rodino waiting period, Nasdaq approval for the new shares and the effectiveness of the planned reverse split. The merger agreement also requires Fulcrum to have at least zero net cash at closing and the $245 million financing agreement to remain in force. The Form S-4 and proxy statement will be the next major documents for Fulcrum investors because they are expected to provide additional detail before shareholders vote on the transaction.